These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22156755)

  • 1. Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.
    Wang L; Fagan AM; Shah AR; Beg MF; Csernansky JG; Morris JC; Holtzman DM
    Alzheimer Dis Assoc Disord; 2012; 26(4):314-21. PubMed ID: 22156755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for ordering of Alzheimer disease biomarkers.
    Jack CR; Vemuri P; Wiste HJ; Weigand SD; Aisen PS; Trojanowski JQ; Shaw LM; Bernstein MA; Petersen RC; Weiner MW; Knopman DS;
    Arch Neurol; 2011 Dec; 68(12):1526-35. PubMed ID: 21825215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
    JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.
    Tardif CL; Devenyi GA; Amaral RSC; Pelleieux S; Poirier J; Rosa-Neto P; Breitner J; Chakravarty MM;
    Hum Brain Mapp; 2018 Feb; 39(2):971-984. PubMed ID: 29164798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
    Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.
    Toledo JB; Xie SX; Trojanowski JQ; Shaw LM
    Acta Neuropathol; 2013 Nov; 126(5):659-70. PubMed ID: 23812320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes.
    Müller-Ehrenberg L; Riphagen JM; Verhey FRJ; Sack AT; Jacobs HIL;
    J Alzheimers Dis; 2018; 66(2):811-823. PubMed ID: 30320590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy.
    Herukka SK; Pennanen C; Soininen H; Pirttilä T
    J Alzheimers Dis; 2008 May; 14(1):51-7. PubMed ID: 18525127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Skouras S; Torner J; Andersson P; Koush Y; Falcon C; Minguillon C; Fauria K; Alpiste F; Blenow K; Zetterberg H; Gispert JD; Molinuevo JL;
    Brain; 2020 Mar; 143(3):976-992. PubMed ID: 32091109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.